Acid addition salt of indene derivative prodrug and method for preparing same

Donepezil ether palmitate acid addition salts, particularly hydrochloride, address the issues of side effects and frequent dosing by stabilizing the compound and providing sustained release, improving treatment compliance and efficacy for dementia.

JP7595162B2Active Publication Date: 2024-12-05CHONG KUN DANG PHARMACEUTICAL CORP
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2023526620
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-11-02
Filing Date
2021-10-27
Publication Date
2024-12-05
Estimated Expiration
2041-10-27

AI Technical Summary

Technical Problem

Donepezil hydrochloride tablets cause gastrointestinal side effects and require frequent administration, leading to poor patient compliance due to their oral formulation, and the indene skeleton in donepezil ether palmitate is prone to intramolecular rearrangement under heat, forming unwanted PT analogs.

Method used

The development of donepezil ether palmitate acid addition salts, such as hydrochloride, which block the amine functional group to prevent PT analog formation and enhance stability, allowing for a sustained release pharmaceutical composition.

Benefits of technology

The acid addition salts of donepezil ether palmitate, like hydrochloride, improve storage stability, reduce side effects, and ensure prolonged and even drug release, enhancing treatment efficacy for dementia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595162000027
    Figure 0007595162000027
  • Figure 0007595162000028
    Figure 0007595162000028
  • Figure 0007595162000029
    Figure 0007595162000029
Patent Text Reader

Abstract

The present invention relates to donepezil ether palmitate hydrochloride (DEP HCl) and a method for producing the same. We have developed donepezil ether palmitate hydrochloride (DEP HCl) with increased stability by suppressing the generation of unknown related substances that are generated during the manufacturing process of the raw material and dosage form of donepezil ether palmitate (DEP). The present invention also relates to a sustained-release pharmaceutical composition containing donepezil ether palmitate hydrochloride (DEP HCl) as a main ingredient, which, when administered to the body, reduces the initial release of the active ingredient donepezil, thereby reducing the risk of side effects such as drug toxicity, and allows donepezil to be released consistently in the body over a long period of time, thereby improving the efficacy of drug treatment for dementia patients.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an acid addition salt of donepezil prodrug and a method for preparing the same. Specifically, the present invention relates to an acid addition salt of donepezil ether palmitate (DEP) and a method for preparing the same, and more particularly to 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(tetradecyloxy)acetate hydrochloride, which has superior storage stability compared to the conventional free base, a pharmaceutical composition containing the same, and a method for preparing the same. [Background technology]

[0002] Dementia is a syndrome that refers to a state in which cognitive function declines due to various diseases occurring in the brain, causing problems in daily life, and the main symptoms include impaired language ability, comprehension, and judgment, as well as personality changes. Alzheimer's disease is the most common degenerative brain disease that causes senile dementia, and although a fundamental treatment has not yet been fully developed, various drugs that can alleviate the symptoms of this disease and slow its progression are in clinical use.

[0003] It has been found that the brains of dementia patients have less of the neurotransmitter acetylcholine (ACh) than healthy people. For this reason, research is being conducted to increase the amount of acetylcholine in the brain or to increase the activity of cholinergic nerve cells.

[0004] A representative drug is an acetylcholinesterase inhibitor. Acetylcholinesterase (AChE), an enzyme that degrades acetylcholine, is an enzyme that hydrolyzes acetylcholine into choline and acetate, and acetylcholinesterase (AChE) inhibitors that inhibit this decomposition enzyme are widely used as treatments for Alzheimer's dementia. A representative acetylcholinesterase (AChE) inhibitor is Donepezil (trade name: Aricept), and oral administration formulations are the most common. However, it is known that oral administration of Donepezil tablets causes gastrointestinal side effects such as diarrhea, vomiting, loss of appetite, and muscle convulsion in some patients. Currently available oral formulations of Donepezil hydrochloride are generally administered once a day at bedtime at 5 mg, and after 4 to 6 weeks of use, the dosage is increased to 10 mg and administered once a day. Therefore, patients need to take the drug orally every day, which greatly reduces compliance with medication. To remedy this, tablets that disintegrate in the oral cavity are commercially available, but these also have the problem that the active ingredient must be administered continuously for a long period of time.

[0005] In order to overcome these problems, donepezil ether palmitate, shown in the following formula 1, has been developed to maintain the drug concentration for a long period of time, reduce the frequency of drug administration, and ultimately improve patient convenience and compliance. [ka]

[0006] However, when studying the raw materials and dosage forms of donepezil ether palmitate in formula 1, it was found that there was a large increase in unknown related substances in addition to the known related substances. After isolating the unknown related substances and carrying out structural analysis, it was found that they were 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-1-yl 2-(tetradecyloxy)acetate (PT related substance) compounds represented by the following formula 2. [ka]

[0007] In relation to this, it has been reported that an intramolecular rearrangement due to hydrogen transfer (1,3-proton transfer) can occur in the indene structure skeleton, as shown in the following reaction scheme 1 (Acta Chemica Scandinavia, 1998, 52, 541-548). [ka]

[0008] This intramolecular rearrangement occurs due to the combined action of three factors: an indene skeleton, an amine base, and heat. This can also be applied to donepezil ether palmitate, which contains an indene skeleton. Since donepezil ether palmitate contains an indene skeleton and an amine functional group in its structure, when heat is applied, a PT analogue of formula 2 can be produced, as shown in the following reaction formula 2. [ka]

[0009] As described above, the present inventors confirmed that the causes of the generation of PT analogues are due to the indene skeleton, amines, and heat, and attempted to develop a donepezil prodrug with increased stability by eliminating these factors, thereby suppressing the generation of PT analogues. [Prior art documents] [Patent documents]

[0010] [Patent Document 1] Japanese Patent Publication No. 11-315016 [Patent Document 2] Korean Patent No. 1980534 [Non-patent literature]

[0011] [Non-Patent Document 1] Acta Chemica Scandinavia, 1998,52,541-548 Summary of the Invention [Problem to be solved by the invention]

[0012] In order to suppress the generation of the PT-related substances, it is necessary to remove one or more of the three elements: the indene structure, the amine, and heat. However, since it is difficult to remove the indene structure, which is the basic structure, and the heat element, the researchers tried to suppress the generation of PT-related substances by blocking the amine functional group.

[0013] Therefore, an object of the present invention is to provide an acid addition salt of donepezil ether palmitate having improved stability by introducing an acid addition salt into donepezil ether palmitate and blocking the basic action of the amine.

[0014] Another object of the present invention is to provide a donepezil ether palmitate acid addition salt, which can reduce the initial release of donepezil, reduce the risk of side effects such as drug toxicity, and release donepezil uniformly in the body for a long period of time, thereby improving the drug therapeutic effect on dementia patients, and a sustained-release pharmaceutical composition containing the same. [Means for solving the problem]

[0015] In order to achieve the above object, the present invention provides an acid addition salt of a compound represented by the following formula 3: [ka]

[0016] In the above formula, R1 is C 12- C 16 is alkyl, The acid may be, but is not limited to, hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid, citric acid, acetic acid, formic acid, fumaric acid, glucaric acid, gluconic acid, glutamic acid, ascorbic acid, benzoic acid, camposulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, oleic acid, orthoic acid, benzenesulfonic acid, tartaric acid, vanillic acid, napadisilic acid, tosylic acid, mesylic acid, succinic acid, ethanesulfonic acid, lactic acid, butyric acid, propionic acid, nicotinic acid, or oxalic acid.

[0017] The present invention provides a sustained release pharmaceutical composition for preventing or treating dementia, comprising the compound of formula 3.

[0018] The present invention provides a donepezil ether palmitate hydrochloride (DEP HCl) compound of formula 4: [ka]

[0019] The present invention also provides a sustained release pharmaceutical composition for preventing or treating dementia, comprising the donepezil ether palmitate hydrochloride (DEP HCl) compound of formula 4.

[0020] The chemical name of the compound of formula 4 is 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(tetradecyloxy)acetate hydrochloride, and in the present invention is referred to as donepezil ether palmitate hydrochloride.

[0021] The donepezil ether palmitate hydrochloride of the present invention can be produced by reacting donepezil ether palmitate with hydrochloric acid.

[0022] The donepezil ether palmitate can be prepared through the following steps: (1) mixing 1-tetradecanol, sodium chloroacetate and potassium hydroxide to obtain sodium 2-(tetradecyloxy)acetate; (2) reacting the sodium 2-(tetradecyloxy)acetate with an aqueous HCl solution to obtain 2-(tetradecyloxy)acetic acid; (3) reacting the 2-(tetradecyloxy)acetic acid with oxalyl chloride to obtain 2-(tetradecyloxy)acetyl chloride; and (4) reacting the 2-(tetradecyloxy)acetyl chloride with donepezil free base.

[0023] The donepezil ether palmitate hydrochloride of the present invention can be prepared through the following steps: (1) 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl adding a solvent to 2-(tetradecyloxy)acetate to dissolve it and prepare a solution; (2) adding an acid to the solution prepared in (1) to form a salt; and (3) A step of stirring the salt produced in (2) to obtain a solid. Effect of the Invention

[0024] The present invention provides donepezil ether palmitate hydrochloride, which can inhibit the production of PT analogues, which are unknown analogues of donepezil ether palmitate, and an efficient method for producing the same.

[0025] Donepezil ether palmitate hydrochloride can not only inhibit the production of PT-related substances, but also raises the melting point of the raw material, and has excellent thermal stability and ease of storage, making it useful as a therapeutic agent for Alzheimer's disease symptoms.

[0026] The donepezil ether palmitate hydrochloride of the present invention exhibits a release pattern far superior to that of donepezil, with less initial release, making it possible to maintain long-term sustained release without rapid drug release, and thus has the effect of improving drug treatment compliance in dementia patients. [Brief description of the drawings]

[0027] [Figure 1] 1 shows the results of nuclear magnetic resonance analysis ( 1 H NMR) of donepezil ether palmitate hydrochloride (DEP HCl) synthesized in Example 6. [Diagram 2] 1 shows the results of nuclear magnetic resonance analysis ( 1 H NMR) of donepezil ether myristate hydrochloride (DEM HCl) synthesized in Example 7. [Diagram 3] 1 shows the results of nuclear magnetic resonance analysis ( 1 H NMR) of donepezil ether pentadecanoate hydrochloride (DEPD HCl) synthesized in Example 8. [Figure 4] 1 shows the results of nuclear magnetic resonance analysis ( 1 H NMR) of donepezil ether heptadecanoate hydrochloride (DEHD HCl) synthesized in Example 9. [Diagram 5] 1 shows the results of nuclear magnetic resonance analysis ( 1 H NMR) of donepezil ether stearate hydrochloride (DES HCl) synthesized in Example 10. [Figure 6] 1 shows differential scanning calorimetry (DSC) analysis data for donepezil ether palmitate hydrochloride (DEP HCl) synthesized in Example 6. [Figure 7] 1 shows differential scanning calorimetry (DSC) analysis data for donepezil ether palmitate (DEP) synthesized in Example 1. [Figure 8] This shows the results of measuring the concentration of donepezil in the blood after administration of donepezil (D) to rats. [Figure 9] This shows the results of measuring the concentration of donepezil in the blood after administration of donepezil ether palmitate hydrochloride (DEP HCl) to rats. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0028] In the following, preferred examples are presented to aid in understanding the present invention. However, the following examples are provided merely to facilitate understanding of the present invention, and are not intended to limit the scope of the present invention.

[0029] In the present invention, Donepezil has the structure of the following formula 9, and its chemical name is 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2,3-hydro-1H-inden-1-one. The Donepezil free base of the present invention may be directly prepared by a known method or may be purchased.

[0030] The present invention relates to an acid addition salt of a compound represented by the following formula 3: [ka]

[0031] In the above formula, R1 is C 12- C 16 is alkyl, The acid is hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid, citric acid, acetic acid, formic acid, fumaric acid, glucaric acid, gluconic acid, glutamic acid, ascorbic acid, benzoic acid, camposulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, oleic acid, orthoic acid, benzenesulfonic acid, tartaric acid, vanillic acid, napadisillic acid, tosylic acid, mesylic acid, succinic acid, ethanesulfonic acid, lactic acid, butyric acid, propionic acid, nicotinic acid, or oxalic acid.

[0032] The present invention relates to donepezil ether palmitate hydrochloride (DEP HCl) of formula 4: [ka]

[0033] The present invention relates to donepezil ether myristate hydrochloride (DEM HCl) of formula 5: [ka]

[0034] The present invention relates to donepezil ether pentadecanoate hydrochloride (DEPD HCl) of formula 6: [ka]

[0035] The present invention relates to donepezil ether heptadecanoate (DEHD HCl) of formula 7: [ka]

[0036] The present invention relates to donepezil ether stearate hydrochloride (DES HCl) of formula 8: [ka]

[0037] The donepezil free base of the present invention may be prepared directly by a known method or may be purchased commercially.

[0038] Various reagents and solvents used in the examples of the present invention were purchased from Sigma-Aldrich Korea, TCI, DAEJUNG CHEMICALS & METALS, etc. The structure of donepezil ether palmitate hydrochloride of the present invention was confirmed by nuclear magnetic resonance analysis ( 1 The differences were confirmed by H NMR and hydrochloride titration (potentiometric titration). Differential scanning calorimetry (DSC) and melting point analysis confirmed that donepezil ether palmitate and its hydrochloride have different physicochemical properties.

[0039] In the present invention, HPLC was performed using an Agilent Technologies 1260 infinity LC. 1 H NMR was measured using a Bruker 400 ultrashield NMR Spectrometer. Purity was measured by HPLC area (%).

[0040] The HPLC conditions used in the present invention to measure the purity of donepezil ether palmitate hydrochloride are as follows.

[0041] 1) Detector: Ultraviolet spectrophotometer (measurement wavelength: 276 nm) 2) Column: YMC-Pack Pro C18 (4.6 x 250 mm, 5 μm) 3) Mobile phase A: 1.88 g of sodium 1-hexanesulfonate was precisely measured and dissolved in 1000 mL of purified water, and then 1.0 mL of phosphoric acid was precisely added. 4) Mobile phase B: Acetonitrile [Table 1] 5) Flow rate: 1.0mL / min 6) Sample: Donepezil ether palmitate hydrochloride 25 mg / mobile phase 10 mL 7) Injection volume: 5μl 8) Column temperature: constant temperature around 50℃

[0042] [Example 1] Preparation of donepezil ether palmitate (DEP) [2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(tetradecyloxy)acetate] [ka]

[0043] 1) Preparation of sodium 2-(tetradecyloxy)acetate (EPS-Na) 400g of 1-tetradecanol was added to the reaction section, and after dissolving at 60°C, 108.7g of sodium chloroacetate and 108mL of normal heptane were added. 78.5g of potassium hydroxide was added to the reaction liquid, which was then heated to 85°C and stirred for 3 hours. 980mL of normal heptane and 2.2L of ethanol (EtOH) were added to the reaction liquid, which was stirred at 60°C for 1 hour, cooled to room temperature, and filtered to obtain 263.3g of sodium 2-(tetradecyloxy)acetate compound. ( 1 H NMR (CDCl3, 400 MHz) δ 3.83(s, 2H), 3.48(t, J=6.9 Hz, 2H), 1.65~1.57(m, 2H), 1.37~1.29(m, 22H), 0.90(t, J=6.9 Hz, 3H)).

[0044] 2) Production of 2-(tetradecyloxy)acetic acid (EPS-acid) In the reaction section, 263.3 g of sodium 2-(tetradecyloxy)acetate prepared in 1) was added to 2.2 L of ethyl acetate (EtOAc) and stirred, then 1.45 L of 2M HCl aqueous solution was poured in and stirred at room temperature for 2 hours. The layers were separated to obtain an organic layer, which was then washed twice with 1.45 L of purified water. The obtained organic layer was washed with 1.45 L of saturated sodium chloride aqueous solution. After obtaining an organic layer, it was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrated compound was dissolved in 1.63 L of normal hexane (n-hexane) and stirred at 0°C for 1 hour. The precipitated solid was filtered to obtain 110.6 g of 2-(tetradecyloxy)acetic acid compound. ( 1 H NMR (CDCl3, 400 MHz) δ 4.11 (s, 2H), 3.56 (t, J=6.7 Hz, 2H), 1.66~1.59 (m, 2H), 1.36~1.25 (m, 22H), 0.88 (t, J=7.2 Hz, 3H)).

[0045] 3) Preparation of 2-(tetradecyloxy)acetyl chloride (EPS-Cl) 50.0 g of 2-(tetradecyloxy)acetic acid prepared in 2) was added to the reaction section, and then 500 mL of dichloromethane and 0.5 mL of dimethylformamide were added and dissolved. 16.5 mL of oxalyl chloride was added to the reaction solution, and the mixture was stirred at room temperature for 3 hours. After the reaction was completed, the solvent was removed by distillation under reduced pressure, and 53.4 g of 2-(tetradecyloxy)acetyl chloride compound was obtained. ( 1 H NMR (CDCl3, 400 MHz) δ 4.39(s, 2H), 3.56(t, J=6.6 Hz, 2H), 1.64~1.57(m, 2H), 1.36~1.25(m, 22H), 0.88(t, J=6.8 Hz, 3H))

[0046] 4) Preparation of 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(tetradecyloxy)acetate (DEP) 63.3g of donepezil free base (purchased from Jinan Chenghui-Shuangda Chemical Co.Ltd) was added to the reaction section, followed by injection of 190mL of tetrahydrofuran and 127mL of DMPU (1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone), dissolution, and cooling to -20℃. 183.5mL of NaHMDS (1.0M THF solution) was injected into the reaction solution for 30 minutes, and the mixture was stirred at -20℃ for 1 hour. The reaction solution was poured into a solution of 53.4 g of 2-(tetradecyloxy)acetyl chloride prepared in the above "Example 1-3)" dissolved in 380 mL of tetrahydrofuran and 253 mL of DMPU (1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone) at -20°C for 40 minutes, and then stirred at the same temperature for 1 hour.

[0047] 630mL of saturated aqueous ammonium chloride solution was poured into the reaction solution, filtered through Celite, and washed with 630mL of ethyl acetate (EtOAc). After layer separation to obtain the organic layer, 630mL of ethyl acetate (EtOAc) was used to back-extract the aqueous layer. The collected organic layer was washed three times with 630mL of 5% aqueous sodium chloride solution. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. 630mL of normal hexane (n-hexane) was poured into the concentrated solution, stirred at 40°C, cooled to room temperature again, and stirred as a slurry for 1 hour. The solution was filtered, and the obtained filtrate was concentrated under reduced pressure. The concentrated solution was purified with a silica column, and then recrystallized with 630mL of normal heptane (n-heptane) to obtain 33.1g of donepezil ether palmitate (DEP).

[0048] ( 1 H NMR (CDCl3, 400 MHz)δ 7.32~7.21(m, 5H), 6.96(s, 1H), 6.59(s, 1H), 4.37(s, 2H), 3.88(s, 3H), 3.87(s, 3H), 3.64(t, J=6.7 Hz, 2H), 3.47(s, 2H), 3.25(s, 2H), 2.87~2.84(m, 2H), 2.27(d, J=7.1 Hz, 2H), 1.90(t, J=10.7 Hz, 2H), 1.71~1.63(m, 4H), 1.55~1.44(m, 1H), 1.41~1.25(m, 24H), 0.88(t, J=6.8 Hz, 3H)

[0049] [Example 2] Preparation of donepezil ether myristate (DEM) [2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(dodecyloxy)acetate]

[0050] 1) Preparation of sodium 2-(dodecyloxy)acetate (EMS-Na) It was prepared by a method similar to that of Example 1-1) using 1-dodecanol. ( 1H NMR (CD3OD, 400 MHz) δ 3.83(s, 2H), 3.47(t, J=6.9 Hz, 2H), 1.64~1.57(m, 2H), 1.37~1.29(m, 18H), 0.90(t, J=6.9 Hz, 3H)).

[0051] 2) Preparation of 2-(dodecyloxy)acetic acid (EMS-acid) The EMS-Na prepared in 1) above was used in a similar manner to that in 2) of Example 1 to prepare the EMS-Na. ( 1 H NMR (CDCl3, 400 MHz) δ 4.11 (s, 2H), 3.56 (t, J=6.7 Hz, 2H), 1.66~1.59 (m, 2H), 1.36~1.25 (m, 18H), 0.87 (t, J=6.9 Hz, 3H)).

[0052] 3) Preparation of 2-(dodecyloxy)acetyl chloride (EMS-Cl) The EMS-Acid prepared in 2) was used in a similar manner to that in 3) of Example 1 to prepare the product. ( 1 H NMR (CDCl3, 400 MHz) δ 4.39(s, 2H), 3.57(t, J=6.6 Hz, 2H), 1.64~1.57(m, 2H), 1.36~1.26(m, 18H), 0.88(t, J=6.8 Hz, 3H)).

[0053] 4) Preparation of 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(dodecyloxy)acetate (DEM) The EMS-Cl prepared in 3) above was used in a similar manner to that in 4) of Example 1 to prepare the compound. ( 1H NMR (CDCl3, 400 MHz)δ 7.32~7.21(m, 5H), 6.96(s, 1H), 6.59(s, 1H), 4.37(s, 2H), 3.87(s, 3H), 3.87(s, 3H), 3.64(t, J=6.7 Hz, 2H), 3.47(s, 2H), 3.25(s, 2H), 2.87~2.84(m, 2H), 2.27(d, J=7.1 Hz, 2H), 1.91(t, J=10.8 Hz, 2H), 1.71~1.63(m, 4H), 1.55~1.44(m, 1H), 1.41~1.25(m, 20H), 0.88(t, J=6.8 Hz, 3H).

[0054] [Example 3] Preparation of Donepezil Ether Pentadecanoate (DEPD) [2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(tridecyloxy)acetate]

[0055] 1) Preparation of sodium 2-(tridecyloxy)acetate (EPDS-Na) It was prepared by a method similar to that of Example 1-1) using 1-tridecanol. ( 1 H NMR (CD3OD, 400 MHz) δ 3.83(s, 2H), 3.47(t, J=6.9 Hz, 2H), 1.64~1.57(m, 2H), 1.37~1.29(m, 20H), 0.90(t, J=6.8 Hz, 3H)).

[0056] 2) Preparation of 2-(tridecyloxy)acetic acid (EPDS-acid) The EPDS-Na prepared in 1) was used in a similar manner to that in 2) of Example 1 to prepare the EPDS-Na. ( 1 H NMR (CDCl3, 400 MHz) δ 4.10(s, 2H), 3.56(t, J=6.7 Hz, 2H), 1.66~1.59(m, 2H), 1.37~1.26(m, 20H), 0.88(t, J=6.8 Hz, 3H)).

[0057] 3) Preparation of 2-(tridecyloxy)acetyl chloride (EPDS-Cl) The EPDS-acid prepared in 2) was used in a similar manner to that in 3) of Example 1 to prepare the product. ( 1 H NMR (CDCl3, 400 MHz) δ 4.39(s, 2H), 3.57(t, J=6.6 Hz, 2H), 1.64~1.57(m, 2H), 1.36~1.26(m, 20H), 0.88(t, J=6.8 Hz, 3H)).

[0058] 4) Preparation of 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(tridecyloxy)acetate (DEPD) The EPDS-Cl prepared in 3) was used in a similar manner to that in 4) of Example 1 to prepare the compound. ( 1 H NMR (CDCl3, 400 MHz)δ 7.32~7.21(m, 5H), 6.96(s, 1H), 6.59(s, 1H), 4.37(s, 2H), 3.87(s, 3H), 3.87(s, 3H), 3.64(t, J=6.7 Hz, 2H), 3.47(s, 2H), 3.25(s, 2H), 2.87~2.84(m, 2H), 2.27(d, J=7.1 Hz, 2H), 1.91(t, J=10.8 Hz, 2H), 1.71~1.63(m, 4H), 1.55~1.44(m, 1H), 1.43~1.25(m, 22H), 0.88(t, J=6.8 Hz, 3H).

[0059] [Example 4] Preparation of Donepezil Ether Heptadecanoate (DEHD) [2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(pentadecyloxy)acetate] 1) Preparation of sodium 2-(pentadecyloxy)acetate (EHDS-Na) It was prepared by a method similar to that of Example 1-1) using 1-pentadecanol. ( 1H NMR (CD3OD, 400 MHz) δ 3.83(s, 2H), 3.47(t, J=6.9 Hz, 2H), 1.64~1.57(m, 2H), 1.37~1.29(m, 24H), 0.90(t, J=6.9 Hz, 3H)).

[0060] 2) Preparation of 2-(pentadecyloxy)acetic acid (EHDS-acid) The EHDS-Na prepared in 1) was used in a similar manner to that in 2) of Example 1 to prepare the product. ( 1 H NMR (CDCl3, 400 MHz) δ 4.11 (s, 2H), 3.56 (t, J=6.7 Hz, 2H), 1.69~1.56 (m, 2H), 1.37~1.25 (m, 24H), 0.88 (t, J=6.8 Hz, 3H)).

[0061] 3) Preparation of 2-(pentadecyloxy)acetyl chloride (EHDS-Cl) The EHDS-acid prepared in 2) was used in a similar manner to that in 3) of Example 1 to prepare the compound. ( 1 H NMR (CDCl3, 400 MHz) δ 4.39(s, 2H), 3.57(t, J=6.6 Hz, 2H), 1.64~1.57(m, 2H), 1.39~1.25(m, 24H), 0.88(t, J=6.8 Hz, 3H)).

[0062] 4) Preparation of 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(pentadecyloxy)acetate (DEHD) The EHDS-Cl prepared in 3) above was used in a similar manner to 4) of Example 1 to prepare the compound. ( 1H NMR (CDCl3, 400 MHz)δ 7.32~7.21(m, 5H), 6.96(s, 1H), 6.59(s, 1H), 4.37(s, 2H), 3.87(s, 3H), 3.87(s, 3H), 3.64(t, J=6.7 Hz, 2H), 3.47(s, 2H), 3.25(s, 2H), 2.87~2.84(m, 2H), 2.27(d, J=7.1 Hz, 2H), 1.91(t, J=10.8 Hz, 2H), 1.71~1.63(m, 4H), 1.53~1.45(m, 1H), 1.41~1.25(m, 26H), 0.88(t, J=6.8 Hz, 3H).

[0063] [Example 5] Preparation of Donepezil Ether Stearate (DES) [2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(hexadecyloxy)acetate] 1) Preparation of sodium 2-(hexadecyloxy)acetate (ESS-Na) It was prepared by a method similar to that of Example 1-1) using 1-hexadecanol. ( 1 H NMR (CD3OD, 400 MHz) δ 3.83(s, 2H), 3.47(t, J=6.8 Hz, 2H), 1.64~1.57(m, 2H), 1.37~1.29(m, 26H), 0.90(t, J=6.8 Hz, 3H)).

[0064] 2) Preparation of 2-(hexadecyloxy)acetic acid (ESS-acid) The ESS-Na prepared in 1) was used in a similar manner to that in 2) of Example 1 to prepare the ESS-Na. ( 1 H NMR (CDCl3, 400 MHz) δ 4.10(s, 2H), 3.57(t, J=6.7 Hz, 2H), 1.66~1.59(m, 2H), 1.37~1.26(m, 26H), 0.88(t, J=6.8 Hz, 3H)).

[0065] 3) Preparation of 2-(hexadecyloxy)acetyl chloride (ESS-Cl) The ESS-acid prepared in 2) was used in a similar manner to that in 3) of Example 1 to prepare the compound. ( 1 H NMR (CDCl3, 400 MHz) δ 4.39(s, 2H), 3.56(t, J=6.6 Hz, 2H), 1.64~1.57(m, 2H), 1.36~1.25(m, 26H), 0.88(t, J=6.8 Hz, 3H)).

[0066] 4) Preparation of 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(hexadecyloxy)acetate (DES) The ESS-Cl prepared in 3) was used in a similar manner to 4) of Example 1 to prepare the compound. ( 1 H NMR (CDCl3, 400 MHz)δ 7.32~7.21(m, 5H), 6.96(s, 1H), 6.59(s, 1H), 4.38(s, 2H), 3.87(s, 3H), 3.87(s, 3H), 3.64(t, J=6.7 Hz, 2H), 3.47(s, 2H), 3.25(s, 2H), 2.87~2.84(m, 2H), 2.27(d, J=7.1 Hz, 2H), 1.91(t, J=10.9 Hz, 2H), 1.71~1.63(m, 4H), 1.52~1.45(m, 1H), 1.41~1.25(m, 28H), 0.88(t, J=6.7 Hz, 3H).

[0067] [Example 6] Preparation of Donepezil Ether Palmitate Hydrochloride (DEP HCl) [2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(tetradecyloxy)acetate hydrochloride] [ka] Donepezil ether palmitate (DEP) (5.0 g, 7.89 mmol) and 100 mL of acetone were added to the reaction section, and the temperature was raised to 40 ° C., and after dissolving, the mixture was cooled to 10 ° C. again. Then, 1 M HCl (7.73 mL, 7.73 mmol) diluted with ethyl acetate (EtOAc) was added dropwise for 1 hour, and the mixture was cooled to 0 ° C. and stirred. After solid precipitation, the mixture was further stirred at 0 ° C. for 30 minutes, and 200 mL of isopropyl ether was added, and the mixture was stirred at the same temperature for 30 minutes. The precipitated solid was filtered and washed with 15 mL of cooled isopropyl ether to obtain 4.86 g of 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(tetradecyloxy)acetate hydrochloride (DEP HCl).

[0068] ( 1 H NMR (CDCl3, 400 MHz)δ 12.42(br, 1H), 7.67~7.57(m, 2H), 7.43~7.39(m, 3H), 6.98~6.93(m, 1H), 6.57~6. 56(m, 1H), 4.40~4.37(m, 2H), 4.17~4.09(m, 2H), 3.87~3.85(m, 6H), 3.63(t, J=6.7 Hz, 2H), 3.43~3.40(m, 2H), 3.25~3.21(m, 2H), 2.57~2.49(m, 2H), 2.40~2.33(m, 2H), 2.1 1~2.02(m, 2H), 1.84~1.80(m, 2H), 1.70~1.61(m, 3H), 1.37~1.24(m, 22H), 0.87(t, J=6.8 Hz, 3H).

[0069] [Example 7] Preparation of Donepezil Ether Myristate Hydrochloride (DEM HCl) [2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(dodecyloxy)acetate hydrochloride] Donepezil ether myristate hydrochloride (DEM HCl) was obtained by a method similar to that of Example 6 using donepezil ether pentadecanoate (DEM) synthesized in Example 2. ( 1 H NMR (CDCl3, 400 MHz)δ 12.44(br, 1H), 7.68~7.58(m, 2H), 7.43~ 7.39(m, 3H), 6.98~6.93(m, 1H), 6.57~6.56(m, 1H), 4.40~4.37(m, 2H), 4.17 ~4.09(m, 2H), 3.87 ~3.85(m, 6H), 3.63(t, J=6.7 Hz, 2H), 3.43~3.40(m, 2H), 3.24~3.21(m, 2H), 2.58~2.50(m, 2H), 2.40~2.33(m, 2H), 2.1 2~2.01(m, 2H), 1.84~1.80(m, 2H), 1.70~1.60(m, 3H), 1.39~1.24(m, 18H), 0.86(t, J=6.8 Hz, 3H).

[0070] [Example 8] Preparation of Donepezil Ether Pentadecanoate Hydrochloride (DEPD HCl) [2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(tridecyloxy)acetate hydrochloride] Donepezil ether pentadecanoate (DEPD) synthesized in Example 3 was used to obtain donepezil ether pentadecanoate hydrochloride (DEPD HCl) in a manner similar to that in Example 6. ( 1 H NMR (CDCl3, 400 MHz)δ 12.39(br, 1H), 7.67~7.57(m, 2H), 7.42~7.38(m, 3H), 6.97~6.92(m, 1H), 6.57~6.55(m, 1H), 4.39~4.37(m, 2H), 4.16~4.08(m, 2H), 3.89 ~3.84(m, 6H), 3.62(t, J=6.7 Hz, 2H), 3.42~3.39(m, 2H), 3.24~3.20(m, 2H), 2.58~2.50(m, 2H), 2.40~2.32(m, 2H), 2.1 1~2.00(m, 2H), 1.82~1.79(m, 2H), 1.69~1.59(m, 3H), 1.38~1.23(m, 20H), 0.86(t, J=6.8 Hz, 3H).

[0071] [Example 9] Preparation of Donepezil Ether Heptadecanoate (DEHD HCl) [2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(pentadecyloxy)acetate hydrochloride] Donepezil ether heptadecanoate (DEHD) synthesized in Example 4 was used to obtain donepezil ether heptadecanoate hydrochloride (DEHD HCl) in a manner similar to that in Example 6. ( 1 H NMR (CDCl3, 400 MHz)δ 12.44(br, 1H), 7.68~7.57(m, 2H), 7.43~7.39(m, 3H), 6.98~6.93(m, 1H), 6.57~6. 56(m, 1H), 4.40~4.37(m, 2H), 4.19~4.09(m, 2H), 3.87~3.85(m, 6H), 3.63(t, J=6.7 Hz, 2H), 3.43~3.40(m, 2H), 3.24~3.21(m, 2H), 2.58~2.50(m, 2H), 2.40~2.33(m, 2H), 2.1 2~2.01(m, 2H), 1.84~1.80(m, 2H), 1.70~1.58(m, 3H), 1.39~1.24(m, 24H), 0.87(t, J=6.8 Hz, 3H).

[0072] [Example 10] Preparation of Donepezil Ether Stearate Hydrochloride (DES HCl) [2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(hexadecyloxy)acetate hydrochloride] Donepezil ether stearate (DES) synthesized in Example 5 was used to obtain donepezil ether stearate hydrochloride (DES HCl) in a similar manner to Example 6. ( 1H NMR (CDCl3, 400 MHz)δ 12.41(br, 1H), 7.67~7.57(m, 2H), 7.42~7.38(m, 3H), 6.97~6.93(m, 1H), 6.57~6. 56(m, 1H), 4.40~4.37(m, 2H), 4.17~4.09(m, 2H), 3.87~3.84(m, 6H), 3.63(t, J=6.7 Hz, 2H), 3.42~3.39(m, 2H), 3.24~3.21(m, 2H), 2.58~2.50(m, 2H), 2.40~2.33(m, 2H), 2.1 1~2.01(m, 2H), 1.83~1.80(m, 2H), 1.69~1.59(m, 3H), 1.38~1.23(m, 26H), 0.86(t, J=6.8 Hz, 3H).

[0073] [Example 11] Preparation of Donepezil Compositions A liquid phase composition was prepared using donepezil (D) and donepezil ether palmitate hydrochloride (DEP HCl).

[0074] The main components (D and DEP HCl), castor oil, and benzyl benzoate were mixed according to the composition and content in Table 1 below, and stirred at room temperature for 0.5 to 3 hours to prepare a liquid phase composition.

[0075] [Table 1]

[0076] [Experimental Example 1] DEP and DEP HCl raw material accelerated stability comparison experiment An experiment was conducted to evaluate the accelerated raw material stability over time of donepezil ether palmitate (DEP) and donepezil ether palmitate hydrochloride (DEP HCl). Specifically, in the experiment, each compound was stored in a light-shielded sealed container under accelerated conditions (40°C, RH 75%), and the chemical stability was analyzed by HPLC (purity and increase in related substances). The results are shown in Table 2. [Table 2] In the case of DEP, even though it was stored in a light-proof sealed container, the PT-related substances increased to 0.13% after 6 months of accelerated storage, and the purity decreased by about 2.47%. In contrast, DEP HCl showed no formation of PT-related substances even after 6 months, and no significant difference was observed from the initial purity, confirming its excellent stability. Therefore, it was confirmed that the DEP HCl of the present invention has superior raw material storage stability under accelerated conditions (40° C., RH 75%) compared to DEP.

[0077] [Experimental Example 2] DEP and DEP HCl raw material severe stability comparison experiment An experiment was conducted to evaluate the raw material stress stability over time of donepezil ether palmitate (DEP) and donepezil ether palmitate hydrochloride (DEP HCl). Specifically, in the experiment, each compound was stored at 60° C., and the chemical stability was analyzed by HPLC (purity and increase in related substances). The results are shown in Table 3. [Table 3] In the case of DEP, PT analogues continued to increase, reaching 4.39% by the second week, and purity decreased by about 18.60% due to an increase in many other analogues. In contrast, DEP HCl of the present invention did not produce any PT analogues, and the overall purity did not change significantly. Therefore, it was found that the DEP HCl of the present invention has superior raw material storage stability even under harsh conditions at a high temperature of 60° C. compared to DEP.

[0078] [Experimental Example 3] Comparative stability study of DEP and DEP HCl formulations A study was conducted to evaluate the formulation stability over time of donepezil ether palmitate (DEP) and donepezil ether palmitate hydrochloride (DEP HCl). Specifically, each DEP and DEP HCl was mixed with benzyl benzoate and castor oil to prepare a suspension, which was then stored at 60°C and 80°C. The chemical stability was analyzed by HPLC (purity and increase in related substances), and the results are shown in Table 4. [Table 4] In the case of DEP, PT analogues increased above the standard under all conditions at 60°C and 80°C. In contrast, DEP HCl of the present invention did not produce any PT analogues under any of the conditions, demonstrating superior stability compared to DEP. Therefore, it was found that the DEP HCl of the present invention is a compound having excellent stability, capable of suppressing the generation of related substances and maintaining high purity for a long period of time.

[0079] [Experimental Example 4] Comparative Experiment of the Physical Properties of DEP and DEP HCl -Differential scanning calorimetry (DSC) analysis The physical properties of donepezil ether palmitate (DEP) and donepezil ether palmitate hydrochloride (DEP HCl) were compared by differential scanning calorimetry (DSC) analysis using a Mettler Toledo DSC 823 differential scanning calorimeter at a scan rate of 10°C per minute under nitrogen, and the results are shown in Table 5. [Table 5] The physical properties of donepezil ether palmitate (DEP) and donepezil ether palmitate hydrochloride (DEP HCl) were compared using a melting point measuring device (MPA100). At this time, the temperature was set to 25°C to 200°C, and the temperature was increased by 5°C per minute to measure the temperature at which each sample completely melted. The results are shown in Table 6. [Table 6] As a result of the above analysis, DEP has a melting point of about 55℃ and is easily dissolved at low temperatures. Such a low melting point means that even short-term exposure to heat is likely to cause changes in the properties and purity of the raw material. In comparison, DEP HCl has a melting point of about 122℃, more than twice as high, and it was confirmed that it does not melt easily. Therefore, it was confirmed that the DEP HCl of the present invention has thermal stability more than twice as high as that of DEP, and has excellent storage stability during storage as a raw material.

[0080] [Experimental Example 5] Comparison of pharmacokinetic evaluation Four male SD rats (rats) weighing an average of 300 g were intramuscularly injected with the donepezil (D) formulation at a dose of 4 mg / kg of donepezil, and with the donepezil ether palmitate hydrochloride (DEP HCl) formulation at a dose of 40 mg / kg of donepezil, and the concentration of donepezil was analyzed from the plasma samples of the SD rats using LC-MS / MS. The results are shown in Table 7, Figure 8, and Figure 9. [Table 7] As shown in Table 7 and Figure 8, when the donepezil composition was administered, the drug was rapidly released immediately after administration, and the Cmax was as high as 27.5 ng·h / mL, which indicated a high possibility of inducing side effects and toxicity. In addition, it was confirmed that the drug release was completed within 3 days, making it unsuitable as a sustained release composition. On the other hand, as shown in Table 7 and Figure 9, when the donepezil ether palmitate hydrochloride composition was administered, despite the administration of an amount equivalent to about 10 times the amount of donepezil, there was no rapid drug release after administration, and the Cmax was low at 13.96 ng·h / mL, confirming that the difference between Cmax and the maintenance concentration was small. Also, unlike the administration of the donepezil composition, it was confirmed that the donepezil ether palmitate hydrochloride composition maintained an effective blood concentration for a period of 8 weeks or more even with a single administration. In the end, it was found that donepezil ether palmitate hydrochloride shows a better release pattern than donepezil. When donepezil ether palmitate hydrochloride is administered into the body, it is possible to maintain sustained release for a long period of time without sudden drug release after administration, and it has excellent properties that allow it to maintain an effective therapeutic drug concentration for a long period of time even with a single administration while minimizing the risk of side effects such as toxic reactions.

Claims

1. An acid addition salt of a compound represented by the following formula 3: 【Chemistry 15】 In the above formula, R 1 is C 12- C 16 is alkyl, The acid is hydrochloric acid.

2. 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(tetradecyloxy)acetate hydrochloride represented by the following formula 4. 【Chemistry 16】

3. A sustained release pharmaceutical composition comprising a compound of formula 3: 【Chemistry 17】 In the above formula, R 1 is C 12- C 16 is alkyl, The acid is hydrochloric acid.

4. A sustained release pharmaceutical composition comprising 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(tetradecyloxy)acetate hydrochloride represented by the following formula 4. 【Chemistry 15】

5. 5. The sustained release pharmaceutical composition according to claim 3 or 4, which is for the prevention or treatment of dementia.

6. A method for producing 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(tetradecyloxy)acetate acid addition salt, comprising the step of reacting 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(tetradecyloxy)acetate with an acid, wherein the acid is hydrochloric acid.

7. (1) adding a solvent to 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(tetradecyloxy)acetate to dissolve it, thereby preparing a solution; (2) adding an acid to the solution prepared in (1) to form a salt; and (3) A step of stirring the salt produced in (2) to obtain a solid; The method for producing 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(tetradecyloxy)acetate acid addition salt according to claim 6, wherein the acid is hydrochloric acid.

8. 8. The method according to claim 7, wherein the solvent is acetone, methanol, ethanol, propanol, isopropyl alcohol, ethyl acetate, isopropyl ether, acetonitrile, tetrahydrofuran, dichloromethane, dioxane, toluene, hexane, heptane, dimethylformamide, dimethylacetamide, or a mixture thereof.

Citation Information

Patent Citations

  • Cyclic amine derivative

    JP1989079151A

  • Preparation or suppository for percutaneous administration containing antidemential agent

    JP1999315016A

  • Prodrug of donepezil hydrochloride which is therapeutic agent for alzheimer type dementia

    JP2008280248A

  • Donepezil myristyloxymethyl ether or its pharmaceutically acceptable salt

    KR101980534B1

  • Donepezil derivative and use thereof

    US20180250278A1